|
|
Prepublished online as a Blood First Edition Paper on April 17, 2002; DOI 10.1182/blood-2002-01-0111.
Submitted January 15, 2002
Accepted February 25, 2002
Factor V Leiden and risk of arterial thrombosis.3 case-control and 3 prospective studies based onThe Copenhagen City Heart Study and 2 meta-analyses
Klaus Juul, Anne Tybjaerg-Hansen, Rolf Steffensen, Steen Kofoed, Gorm Jensen, and Borge G Nordestgaard*
Clinical Biochemistry, Herlev University Hospital, Herlev, Denmark
Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; The Copenhagen City Heart Study, Bispebjerg University Hospital, Bispebjerg, Denmark
Medicine B, Hillerod Hospital, Hillerod, Denmark
Vascular Surgery, Gentofte University Hospital, Gentofte, Denmark
The Copenhagen City Heart Study, Bispebjerg University Hospital, Bispebjerg, Denmark
Clinical Biochemistry, Herlev University Hospital, Herlev, Denmark; The Copenhagen City Heart Study, Bispebjerg University Hospital, Bispebjerg, Denmark
* Corresponding author; email: brno{at}herlevhosp.kbhamt.dk.
Background: Factor V Leiden (FVL) is associated with venous thrombosis; however, an association between FVL and arterial thrombosis remains controversial.
Objective: We investigated FVL as a risk factor for myocardial infarction (MI), ischemic stroke (IS), or non-MI ischemic heart disease (non-MI-IHD).
Design: 3 case-control studies and 3 prospective studies with 21 years follow-up.
Setting: General population, Copenhagen, Denmark.
Participants: Copenhagen City Heart Study 20-95 year old participants without cardiovascular disease (=control population, n=7,907) or participants diagnosed with MI (n=469), IS (n=231) or non-MI-IHD (n=365). In addition, 3 independent patient populations from Copenhagen University Hospital with MI (n=493), IS (n=231) or non-MI-IHD (n=448).
Measurements: FVL genotype, major cardiovascular risk factors, MI, IS, and non-MI-IHD incidence and prevalence.
Results: Prevalences of FVL heterozygotes and homozygotes in controls from the general population were 7.7% and 0.2%. Odds ratios and relative risks of MI in FVL carriers (=heterozygotes+homozygotes) vs. non-carriers were 1.24 (95% CI: 0.91-1.69) and 0.83 (0.58-1.20) in case-control and prospective studies, respectively. Corresponding risks for IS were 0.92 (0.56-1.53) and 0.68(0.45-1.04), and for non-MI-IHD 1.01 (0.71-1.44) and 0.97 (0.66-1.42).
Conclusion: Findings from The Copenhagen City Heart Study suggest that FVL is not associated with MI, IS or non-MI-IHD.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
B. Dahlback
Advances in understanding pathogenic mechanisms of thrombophilic disorders
Blood,
July 1, 2008;
112(1):
19 - 27.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. KAMINSKI, C. D. TAN, and A. T. ASKARI
A young man with acute weakness of his right arm
Cleveland Clinic Journal of Medicine,
February 1, 2008;
75(2):
145 - 152.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. C. Aird
Phenotypic Heterogeneity of the Endothelium: I. Structure, Function, and Mechanisms
Circ. Res.,
February 2, 2007;
100(2):
158 - 173.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al.
Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline.
Circulation,
June 20, 2006;
113(24):
e873 - e923.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al.
Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline.
Stroke,
June 1, 2006;
37(6):
1583 - 1633.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Juul, A. Tybjaerg-Hansen, S. Marklund, P. Lange, and B. G. Nordestgaard
Genetically Increased Antioxidative Protection and Decreased Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med.,
April 15, 2006;
173(8):
858 - 864.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Sacco, R. Adams, G. Albers, M. J. Alberts, O. Benavente, K. Furie, L. B. Goldstein, P. Gorelick, J. Halperin, R. Harbaugh, et al.
Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline.
Circulation,
March 14, 2006;
113(10):
e409 - e449.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Sacco, R. Adams, G. Albers, M. J. Alberts, O. Benavente, K. Furie, L. B. Goldstein, P. Gorelick, J. Halperin, R. Harbaugh, et al.
Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline.
Stroke,
February 1, 2006;
37(2):
577 - 617.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Goodyear, K. Piper, N. Khan, J. Starczynski, P. Mahendra, G. Pratt, and P. Moss
CD8+T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden
Blood,
December 15, 2005;
106(13):
4217 - 4224.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Juul, A. Tybjaerg-Hansen, J. Mortensen, P. Lange, J. Vestbo, and B. G. Nordestgaard
Factor V Leiden Homozygosity, Dyspnea, and Reduced Pulmonary Function
Arch Intern Med,
September 26, 2005;
165(17):
2032 - 2036.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Lalouschek, M. Schillinger, K. Hsieh, G. Endler, S. Tentschert, W. Lang, S. Cheng, and C. Mannhalter
Matched Case-Control Study on Factor V Leiden and the Prothrombin G20210A Mutation in Patients With Ischemic Stroke/Transient Ischemic Attack Up to the Age of 60 Years
Stroke,
July 1, 2005;
36(7):
1405 - 1409.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. T. Eitzman, R. J. Westrick, Y. Shen, P. F. Bodary, S. Gu, S. L. Manning, S. L. Dobies, and D. Ginsburg
Homozygosity for Factor V Leiden Leads to Enhanced Thrombosis and Atherosclerosis in Mice
Circulation,
April 12, 2005;
111(14):
1822 - 1825.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Dahl, B G Nordestgaard, and N Seersholm
{alpha}1-Antitrypsin genotype unaffected by age * Authors' reply
Thorax,
March 1, 2005;
60(3):
258 - 259.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Frederiksen, K. Juul, P. Grande, G. B. Jensen, T. V. Schroeder, A. Tybjaerg-Hansen, and B. G. Nordestgaard
Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study
Blood,
November 15, 2004;
104(10):
3046 - 3051.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Casas, A. D. Hingorani, L. E. Bautista, and P. Sharma
Meta-analysis of Genetic Studies in Ischemic Stroke: Thirty-two Genes Involving Approximately 18 000 Cases and 58 000 Controls
Arch Neurol,
November 1, 2004;
61(11):
1652 - 1661.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. S. Donahue
Factor V Leiden and Perioperative Risk
Anesth. Analg.,
June 1, 2004;
98(6):
1623 - 1634.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Dahl, A. Tybjaerg-Hansen, P. Schnohr, and B. G. Nordestgaard
A Population-based Study of Morbidity and Mortality in Mannose-binding Lectin Deficiency
J. Exp. Med.,
May 17, 2004;
199(10):
1391 - 1399.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. E. Humphries, P. M. Ridker, and P. J. Talmud
Genetic Testing for Cardiovascular Disease Susceptibility: A Useful Clinical Management Tool or Possible Misinformation?
Arterioscler Thromb Vasc Biol,
April 1, 2004;
24(4):
628 - 636.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Juul, A. Tybjaerg-Hansen, P. Schnohr, and B. G. Nordestgaard
Factor V Leiden and the Risk for Venous Thromboembolism in the Adult Danish Population
Ann Intern Med,
March 2, 2004;
140(5):
330 - 337.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P. Tracy
Thrombin, Inflammation, and Cardiovascular Disease: An Epidemiologic Perspective
Chest,
September 1, 2003;
124
(2009):
49S - 57S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. S. Donahue, D. Gailani, M. S. Higgins, D. C. Drinkwater, and A. L. George Jr
Factor V Leiden Protects Against Blood Loss and Transfusion After Cardiac Surgery
Circulation,
February 25, 2003;
107(7):
1003 - 1008.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
